Startups
Integra Therapeutics
Barcelona biotechnology company developing gene-writing tools for advanced cell and gene therapies. Its FiCAT platform combines CRISPR-Cas targeting with an engineered piggyBac transposase to insert small or large genetic payloads with precise, stable genome integration. Founded as a Pompeu Fabra University spin-out by Marc Güell and Avencia Sánchez-Mejías, Integra is developing the platform for preclinical CAR-T therapies and other cell-engineering applications, alongside a gene therapy for a rare paediatric liver disease. Its work includes protein engineering and AI-assisted design; these programs remain in development.
Founded 2020
Team
Avencia Sánchez-MejíasCo-Founder, Chief Executive Officer and Board Member |
Clément BertholetBoard Member |
Cédric FeschotteScientific Advisory Board Member; DNA Transposases |
Damià TormoBoard Member |
George ChurchChairman, Scientific Advisory Board |
Jiaping GuBoard Member |
Luis ParerasBoard Member |
Marc GüellCo-Founder, Chief Scientific Officer and Board Member |
Margot PontVice President, Translational Development |
Mark BonyhadiBoard Member, Independent Director and Scientific Advisory Board Member |
 Miles GersonIndependent Chairman |
Noelia FerruzScientific Advisory Board Member; Protein Engineering and AI |
Richard J. ThompsonScientific Advisory Board Member; Paediatric Hepatology |
Simon DewChief Business Officer |